Lorus' Virulizin Demonstrates Excellent Anti-Tumor Activity In Human Breast Cancer Tumors In Pre-Clinical Tests.Business Editors TORONTO--(BUSINESS WIRE)--Jan. 9, 2001 Lorus Therapeutics (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :LORFF)(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :LOR LOR Letter Of Reprimand (military) LoR Lord of the Rings (J.R.R. Tolkien) LOR Learning Object Repository LOR Linux.Org. .) Pre-Clinical Data Suggests Virulizin(R) is More Effective in Reducing Tumor Growth Than Taxol Lorus Therapeutics Inc. ("LORUS") announced today that its lead anti-cancer drug Virulizin(R) demonstrated better anti-tumor activity in mice containing human breast cancer tumor cells than Taxol, one of the current standard treatments available for breast cancer. Additional findings revealed that the most outstanding anti-tumor activity occurred when Virulizin(R) and Taxol were used in combination. Significant tumor growth inhibition Growth inhibition (GI) is a medical term pertaining to cancer therapy and the specific reduction in growth of tumors and oncogene cells by a chemical compound, mechanical therapy (e.g. was observed in two independent tests with a total of 20 mice, including tumor regressions in nine of these mice, of which six experienced complete tumor regressions. These observations were made following a four-week treatment with Virulizin(R). In another study, Lorus found that when treatments with Virulizin(R) and Taxol were combined the anti-tumor activity was the most significant and led to tumor regressions in 15 of 20 mice; eight of which were total regressions. According to the Canadian Breast Cancer Foundation The Canadian Breast Cancer Foundation is a charitable organization which raises money to advance research, education, diagnosis and treatment of breast cancer. Established in 1986, it works to fund, support, and advocate for education and awareness programs, early diagnosis and , one out of nine Canadian women will develop breast cancer and one in 26 will die from the disease. Breast cancer is the leading cause of death among females between the ages of 35 and 49. "In pre-clinical studies and clinical trials, Virulizin(R) has proven to be a safe and effective multi-purpose drug capable of anti-tumor activity in a range of cancer types, such as pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. and malignant melanoma Malignant Melanoma Definition Malignant melanoma is a type of cancer arising from the melanocyte cells of the skin. Melanocytes are cells in the skin that produce a pigment called melanin. ," said Dr. Jim Wright, president, Lorus. "These results further confirm the anti-tumor activity of Virulizin(R) in a standard pre-clinical model of human cancer, and demonstrate its potential for the treatment of an often devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. disease in women." Lorus recently reported that Virulizin(R) was effective against human pancreatic tumor cells, which are resistant to gemcitabine, the standard treatment for advanced pancreatic cancer. In addition, the company plans to file for an Investigational New Drug Application (IND) to begin a Phase III trial for Virulizin(R) in North America. About Lorus Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol LOR, and on the OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB exchange under the symbol LORFF. Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 40-F filings. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: www.lorusthera.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion